Cenobamate as a Promising Treatment for Patients With Epilepsy

In November 2019, cenobamate (Xcopri; SK Life Science) was FDA-approved as a medication for partial-onset seizures and since has received a lot of attention in the clinical field of epilepsy. The treatment, a sodium channel antagonist, had its safety and efficacy assessed and confirmed in 2 previous pivotal trials: Study 013 (NCT01397968) and Study 017 (NCT01866111). Since the completion of those trials, the profile of cenobamate has expanded with further analyses from these studies. Recently, at the 2023 American Academy of Neurology (AAN) Annual Meeting, April 22-27, in Boston, Massachusetts, investigators presented additional research highlighting the therapeutic. In total, SK Life Science presented 10 abstracts, including post-hoc analyses on the rate of sudden unexpected death in epilepsy (SUDEP) and drug load in adults with partial-onset (focal) seizures taking cenobamate tablets. William E. Rosenfeld, MD, FAAN, FAES, neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri,recently sat down with NeurologyLive® in an interview to speak about the latest research on cenobamate that was presented during the meeting. He talked briefly about the 3 studies that he coauthored, as well as the significance of cenobamate’s impact on seizure. Rosenfeld also spoke about the importance of defined daily dose for patients and other critical factors observed in the study. (https://www.neurologylive.com/view/cenobamate-promising-treatment-patients-epilepsy-william-rosenfeld) VIew More AAN Content: https://www.neurologylive.com/conferences/aan